ALK and non-small cell lung carcinoma: NSCLC comprises up to 85% of lung cancer in the US, with development being due to driver mutations of different tyrosine kinases like KRAS, EGFR, ALK, ROS1, MET, RET, NTRK, human epidermal growth factor receptor 2 (HER2), and BRAF[79,80].